OP2113

About CVasThera

CVasThera is a Paris-based, privately-held biotech founded in 2016 by seasoned pharmaceutical executives. It operates as a project accelerator, identifying and developing small molecule drug candidates, primarily in cardiovascular and gastrointestinal diseases, through a model built on expert guidance, funding access, and strategic intellectual property management. The company's pipeline includes partnered and internal programs at pre-clinical stages, supported by research grants and collaborations with academic and industry partners. Its core value proposition is de-risking and accelerating early-stage biopharmaceutical projects for partners and its own portfolio.

Therapeutic Areas

Other Acute Myocardial Infarction Drugs